Matters: The company announced the 2016 third quarterly report: the first three quarters achieved revenue of 2.525 billion yuan, an increase of 27.83%; the net profit attributable to the company reached 544 million yuan, an increase of 30.77%. Basically in line with market expectations.
Peaceful point of view:
Cardiovascular product service plus code to ensure long-term growth:
The closed-loop prototype of the company's cardiovascular field has been completed. In terms of products, the medical machinery segment achieved revenue of 1.554 billion yuan in the first three quarters, a year-on-year increase of 23.82%. The core support business continues to grow by around 15% with the popularity of NANO. The IVD sector, which is centered on heart marker detection, has maintained a high growth trend for three years, and this year's growth rate is expected to remain above 60%. In October, the company's dual-chamber pacemaker was approved, becoming the only dual-chamber pacemaker in China, opening the 5 billion potential dual-chamber market. In the first three quarters of the pharmaceutical sector, revenue reached 833 million yuan, a year-on-year increase of 25.96%. Lepu Pharmaceutical relies on clopidogrel to achieve double growth, and the remaining 40% stake in Lepu Pharmaceuticals has been completed in March, further increasing profits. New Donggang, which was acquired in early 2015, is undergoing a transition to the reagent business, with significant profit growth. In 2016, the company newly acquired Meihua Pharmaceutical (100%), Yongzheng Pharmaceutical (75%), Hengjiuyuan Pharmaceutical (60%), and expanded its cardiovascular drug product line to the field of hypertension.
In terms of services, the company's prenatal screening has begun to take shape, and accurate drug guidance and testing services are also expected to be launched one after another, forming synergy with the use of the company's medical and pharmaceutical products. The Lepu three-level network hospital is under continuous construction. The Luoyang Sixth Hospital was acquired in February and the Hefei High-tech Cardiovascular Hospital in August was used as a regional center. The number of grassroots pharmacy clinics has reached more than 300, completing the long-term layout. 1/5 of the target.
Other areas continue to expand, building a large health platform: Outside the cardiovascular field, the company has more water testing, excavator in the field of large health. Since 2016, we have developed high-precision protein detection (Quanterix), blood purification (Ruijian Medical ), monoclonal antibody (Jun Shi biological), insulin needle-free syringe (Quick Shure) through the participation of stocks or fund investment, and have independently developed and approved ultrasound. Cirrhosis tester. The layout of these fields enables the company to build a large health platform and maintain new opportunities to ensure long-term development while maintaining a strong cardiovascular strength.
Chilli pepper
Chilli pepper
Laiwu Manhing Vegetables Fruits Corporation , https://www.manhingfood.com